Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07099898 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) | PHASE3 | RECRUITING | 420 | — | — | Aug 11, 2025 | Sep 28, 2029 | May 27, 2026 | 120 | Argentina, Australia +22 |
OS is defined as the time from the date of randomization to the date of death by any cause
| Arm | Type | Description |
|---|---|---|
| Ris-Rez | EXPERIMENTAL | - |
| Topotecan | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ris-Rez | BIOLOGICAL | Ris-Rez will be administered |
| Topotecan | DRUG | Topotecan will be administered |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Adults \>18 or the minimum legal adult age at the time the informed consent form is signed * Has histologically or cytologically confirmed extensive-stage small cell lung cancer...